Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | LSS | P48449 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 2/20 | 0.39 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 4/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8855135 | 0.98 | SIGMAR1 (0.66) | SIGMAR1CYP1A2LSSKDM5APHF8 | |
| SCHEMBL8711529 | 0.98 | SIGMAR1 (0.66) | SIGMAR1CYP1A2LSSKDM5APHF8 | |
| SCHEMBL10324315 | 0.98 | SIGMAR1 (0.59) | SIGMAR1CYP1A2LSSKDM5APHF8 | |
| Hydrochloric Acid SCHEMBL9518737 | 0.96 | SIGMAR1 (0.63) | SIGMAR1CYP1A2LSSKDM5APHF8 | |
| Hydrochloric Acid SCHEMBL9516763 | 0.96 | SIGMAR1 (0.63) | SIGMAR1CYP1A2LSSKDM5APHF8 | |
| Water SCHEMBL9246810 | 0.96 | SIGMAR1 (0.63) | SIGMAR1CYP1A2LSSKDM5APHF8 | |
| Water SCHEMBL9249880 | 0.96 | SIGMAR1 (0.63) | SIGMAR1CYP1A2LSSKDM5APHF8 | |
| Hydrochloric Acid SCHEMBL9520541 | 0.96 | SIGMAR1 (0.63) | SIGMAR1CYP1A2LSSKDM5APHF8 | |
| Water SCHEMBL9249103 | 0.96 | SIGMAR1 (0.63) | SIGMAR1CYP1A2LSSKDM5APHF8 | |
| Water SCHEMBL9246924 | 0.96 | SIGMAR1 (0.63) | SIGMAR1CYP1A2LSSKDM5APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2663400-A1 | PROCESS OF MAKING MODIFIED METALLOCENE CATALYST, CATALYST PRODUCED AND USE THEREOF | W. R. Grace & Co.-Conn (US) | 2013-11-20 | — | — | EP | claimed |
| WO-2012097146-A1 | PROCESS OF MAKING MODIFIED METALLOCENE CATALYST, CATALYST PRODUCED AND USE THEREOF | W. R. GRACE & CO.-CONN. (US) | 2012-07-19 | — | — | WO | claimed |
| WO-2008153701-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2008-12-18 | — | — | WO | claimed |
| EP-1707563-A2 | Methods and compositions utilizing quinazolinones | Cytokinetics, Inc. (US) | 2006-10-04 | — | — | EP | claimed |
| EP-1686120-A2 | Methods and compositions utilizing quinazolinones | Cytokinetics, Inc. (US) | 2006-08-02 | — | — | EP | claimed |
| US-20040023996-A1 | Methods and compositions utilizing quinazolinones | CYTOKINETICS, INC. | 2004-02-05 | — | — | US | claimed |
| US-6562831-B1 | Inhibitors of the mitotic kinesin KSP and are useful in the treatment of cellular proliferative diseases | CYTOKINETICS, INC. | 2003-05-13 | — | — | US | claimed |
| EP-1296959-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | Cytokinetics, Inc. (US) | 2003-04-02 | — | — | EP | claimed |
| WO-2001030768-A9 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS INC (US) | 2002-08-15 | — | — | WO | claimed |
| EP-1226129-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | Cytokinetics, Inc. (US) | 2002-07-31 | — | — | EP | claimed |
| WO-2001098278-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS, INC. (US) | 2001-12-27 | — | — | WO | claimed |
| WO-2001030768-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS, INC. (US) | 2001-05-03 | — | — | WO | claimed |
| US-8658656-B2 | Methods and compositions utilizing quinazolinones | CYTOKINETICS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8633236-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2663400-A1 | PROCESS OF MAKING MODIFIED METALLOCENE CATALYST, CATALYST PRODUCED AND USE THEREOF | W. R. Grace & Co.-Conn (US) | 2013-11-20 | — | — | EP | disclosed |
| US-8470838-B2 | Quinazolinones useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide monomethanesulfonate; treating breast cancer | CYTOKINETICS, INCORPORATED (US) | 2013-06-25 | — | — | US | disclosed |
| WO-2003088903-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |
| US-6630479-B1 | Cell proliferative diseases and disorders associated with KSP kinesin activity | CYTOKINETICS, INC. | 2003-10-07 | — | — | US | disclosed |
| US-6562831-B1 | Inhibitors of the mitotic kinesin KSP and are useful in the treatment of cellular proliferative diseases | CYTOKINETICS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-6545004-B1 | Treating cellular proliferative diseases and disorders associated with KSP kinesin activity. | CYTOKINETICS, INC. | 2003-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023996-A1 | Methods and compositions utilizing quinazolinones | KIF5B, KIF5C, KIF2C | SIGMAR1 3804/4885CYP1A2 3695/4885LSS 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.